Partner Headlines - LLY

  1. Top Funds Heart Edward Lifesciences, Bump Lilly

    IBD
  2. Merck Stock Slides As Q4 Revenue, Guidance Miss Expectations

    IBD
  3. Earnings Recap For January 28

    Benzinga
  4. Eli Lilly Punished For Inline Report

    Benzinga
  5. JNJ Kicks Off Health Care Earnings—What About Deals, Buybacks?

    Benzinga
  6. Stock Marquee Crowded With Oil, Apple, and the Fed

    Benzinga
  7. Last-Hour Rally Erases Midday Losses As Indexes Close Mixed

    IBD
  8. Steven Cohen Makes Eli Lilly, Kraft Heinz Top New Buys

    GuruFocus
  9. A Calmer Year For Pharma?

    IBD
  10. 3 Potential Blockbuster Drugs Launching in 2016

    IBD
  11. Lilly Counts On Pipeline In '16

    IBD
  12. Lilly Guidance Misses Estimates On Lower Sales

    IBD
  13. The 5 Top-Performing Big-Cap Drug Stocks Of 2015

    IBD
  14. 5 Top Stocks of the Outperforming Vanguard Health Care Fund

    GuruFocus
  15. Mairs and Power Sells Baxalta, Walt Disney, Target

    GuruFocus
  16. Strategic Beta ETFs Among Year's Top Performers

    IBD
  17. Benzinga's Top Upgrades

    Benzinga
  18. GoPro PT Cut; Chipotle, Bluebird Bio Downgraded

    IBD
  19. Cautious Stock Rebound as Jobs Data Delivers But Wages Still ...

    Benzinga
  20. Lilly Ends Basal Insulin Peglispro Development Program

    Benzinga
  21. HOTCHKIS & WILEY Buys More Than 7 Million Shares in Oil and Gas ...

    GuruFocus
  22. Merck

    IBD
  23. 3 Big Pharma Upgrades (And One Downgrade) At Barclays

    IBD
  24. Amazon's PT Raised; Yum, J&J, Merck, Lilly Upgraded

    IBD
  25. Benzinga's Top Upgrades

    Benzinga
  26. Sanofi Chipping Away At Biogen's MS Dominance

    IBD
  27. Steven Cohen Hikes Stake in Microsoft by More Than 50,000%

    GuruFocus
  28. Biotechs Weaken, But These Names Have Bullish Charts

    IBD
  29. Eli Lilly Release Confirms FDA Approval If Portrazza

    Benzinga
  30. Lilly and Merck Expand Immuno-oncology Collaboration with Phase ...

    Benzinga
  31. Goldman Sachs' Top 4 Smid-Cap Biotech Picks

    IBD
  32. PRIMECAP Sells Stake in Technology Company

    GuruFocus
  33. Benzinga's Top Upgrades

    Benzinga
  34. ELI LILLY

    IBD
  35. Lilly, Incyte Announce Data Demonstrate Baricitinib Superiority ...

    Benzinga
  36. DOJ Eyes Lilly, Merck Pricing

    IBD
  37. How This Top Stock Mutual Fund Manager Seeks Growth

    IBD
  38. How This Top Stock Mutual Fund Manager Seeks Growth

    IBD
  39. Sanofi, Novo Nordisk Slide On Diabetes Headwinds

    IBD
  40. Lilly and Incyte Announce Webcast to Discuss Baricitinib Phase ...

    Benzinga
  41. Eli Lilly Q3 Earnings, Guidance Beat On Cost Control

    IBD
  42. Eli Lilly CEO: Our Drug Prices are Fair

    FoxBusiness
  43. McDonald's Strong 3Q Helps Wall Street Jump

    FoxBusiness
  44. Eli Lilly Posts Upbeat Q3 Earnings, Raises Forecast

    Benzinga
  45. Eli Lilly Reports Mixed 3Q Results

    FoxBusiness
  46. Lilly supports global Dementia Discovery Fund

    Benzinga
  47. Wal-Mart's $21 Billion Loss Lost on NYSE Officials

    FoxBusiness
  48. Lilly-Incyte drug beats Humira

    IBD
  49. Lilly-Incyte Drug Beats Humira In Arthritis Trial

    IBD
  50. US Stock Futures Down; JPMorgan Earnings In Focus

    Benzinga
  51. Lilly and ImaginAb Announce Preclinical Immuno-Oncology Collaboration, ...

    Benzinga
  52. Fast Money Traders Share Their Thoughts On Eli Lilly and And ...

    Benzinga
  53. Eli Lilly Pulls Cholesterol Drug

    IBD
  54. Indexes Close Up Across The Board; Facebook Gains, But Twitter ...

    IBD
  55. Stocks Near Flatline; Bad News for Lilly Is Good News For Regeneron

    IBD
  56. Regeneron Stock Pops But Hits Resistance At 50-Day

    IBD
  57. Lilly Kills 'High Risk/High Reward' Cholesterol Drug

    IBD
  58. Stocks Poised For Modestly Higher Start; EMC Jumps In Premarket

    IBD
  59. US Stock Futures Flat Ahead Of Fed Speakers

    Benzinga
  60. Lilly, Innovent Biologics Expand Their Strategic Alliance

    Benzinga
  61. Eli Lilly

    IBD
  62. Lilly Upgraded On Bullish Diabetes Outlook

    IBD
  63. Benzinga's Top Upgrades

    Benzinga
  64. Lilly Receives FDA Breakthrough Therapy Designation for Abemaciclib ...

    Benzinga
  65. A Cholesterol Drug Revolution

    IBD
  66. Are Cholesterol Drugs In For Another Revolution?

    IBD
  67. Morning Market Losers

    Benzinga
  68. Despite EU OK, Regeneron Crumbles Below 200-Day

    IBD
  69. Lilly's CYRAMZA® (ramucirumab) Significantly Improves Progression-Free ...

    Benzinga
  70. AbbVie Spurns Galapagos To Advance Own Arthritis Drug

    IBD
  71. Forget The 2016 Election Candidates, CEOs Are Driving Change

    Benzinga
  72. Lilly's New Diabetes Drug Delivers "One of a Kind" Results

    FoxBusiness
  73. Benzinga's Top Initiations

    Benzinga
  74. U.S. District Court Rules in Lilly's Favor on Alimta Vitamin ...

    Benzinga
  75. Benzinga's Volume Movers

    Benzinga
  76. Lilly Issues Update on Evacetrapib Phase 3 Trial: Last Patient ...

    Benzinga
  77. Biogen's Big-Volume Plunge Marks End Of 5-Year Run

    IBD
  78. Valeant Posts Princely Gains

    IBD
  79. 3 Big-Cap Drugmakers Who Beat Q2 Earnings Estimates

    IBD
  80. Shire Lifts 2015 Guidance On Strong Drug Pipeline

    IBD
  81. Lilly, Bristol-Myers Beat Q2 Views, Lift Guidance

    IBD
  82. Valeant Earnings Soar On M&A, Organic Sales Growth

    IBD
  83. Wall Street Struggles for Direction After Two-Day Selloff

    FoxBusiness
  84. Alzheimer's Data Diverge

    IBD
  85. Biogen, Lilly Alzheimer's Data Spark Street Debate

    IBD
  86. Are We Any Closer to Finding a Drug to Battle Alzheimer's?

    FoxBusiness
  87. Data Using New Delayed-Start Methodology Suggested Benefit of ...

    Benzinga
  88. Fast Money Picks For July 21

    Benzinga
  89. 6 Big-Cap Drugmakers Reporting Earnings Next Week

    IBD
  90. Celgene Hits High As Street Applauds Receptos Buyout

    IBD
  91. Manning & Napier Advisors' Most Weighted Trades in Q2 2015

    GuruFocus
  92. Weekly 52-Week Highs Highlight: LLY, PLL, SBUX, VLO

    GuruFocus
  93. Eli Lilly Shares Go Parabolic

    Benzinga
  94. Stocks Cling To Thin Early Gains; Ambarella Bounces, Cree Dives

    IBD
  95. Alder Bio Up As Credit Suisse Lauds Migraine Drug

    IBD
  96. Bristol-Myers Squibb Takes A Step Up On Cancer Drugs, But The ...

    GuruFocus
  97. Where Can Mega-Drug Stock Gilead Sciences Go Now?

    IBD
  98. Teva Migraine Drug Succeeds In Midstage Trial

    IBD
  99. Teva Migraine Drug Succeeds In Midstage Trial

    IBD
  100. Benzinga's Top Initiations

    Benzinga
Trading Center